Market closed

Alumis Inc./$ALMS

Alumis shares are trading higher after stockholders approved a merger with ACELYRIN and the company reported its Q1 results.
7 hours ago·Lightyear AI
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Alumis Inc.

Alumis Inc is a clinical-stage biopharmaceutical company focused on identifying, acquiring, and accelerating the development and commercialization of transformative medicines for autoimmune disorders. The Company leverages its proprietary precision data analytics platform, biological insights, and a team of experts with deep experience in precision medicine drug discovery, development, and immunology, to create medicines that significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Company pipeline includes: ESK-001, TYK2, A-OO5, IRF5.

Ticker

$ALMS
Trading on

Industry

Pharmaceuticals

Employees

169

ISIN

US0223071020

Alumis Inc. Metrics

BasicAdvanced
$245M
-
-$10.38
-
-
$245M
$10.49
$3.18
553K
6.014
5.662
11.213
11.811
-87.31%
-198.66%
0.94
0.94
-0.498
-85.60%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $ALMS

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs

What’s the current market cap for Alumis Inc. stock?

What is the P/E ratio for Alumis Inc. stock?

Does Alumis Inc. stock pay dividends?

When is the next Alumis Inc. dividend payment date?

What is the beta indicator for Alumis Inc.?